Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Anchorage-independent growth of tumor cells constitutes a phenotype highly associated with malignant transformation and appears to be important in the ultimate event of tumor metastasis, i.e., secondary tumor colonization. The role of a specific, melanoma-associated chondroitin sulfate proteoglycan population in anchorage-independent growth was assessed. Melanoma cells cultured in soft agar containing monoclonal antibody (mAb) 9.2.27, which recognizes such molecules on the surface of these cells, showed a 67-74% specific decrease in their colony formation. In contrast, neither mouse myeloma IgG nor monoclonal anti-HLA-A,B,C antibody (W6/32) had any effect on colony formation of the melanoma cells grown in soft agar. Human melanoma cells cultured in the presence of mAb 9.2.27 or W6/32 did not exhibit any changes in their DNA or protein synthetic metabolism. These findings suggest that 9.2.27-defined chondroitin sulfate proteoglycans on the surface of human melanoma cells may be involved in cell--cell interaction important in anchorage-independent growth.
 ...
PMID:Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan. 657 84

Two patients are presented who had a resection of a solitary expansile rib lesion. The radiologic features were nonspecific and the lesions were thought to represent either fibrous dysplasia, myeloma, or metastatic disease. Histologically, the lesion consisted of focal hyperplasia of the bone marrow involving all hematopoietic elements. The marrow expanded the rib, eroded the cortex, and extended into the adjacent soft tissue. Neither patient had any underlying hematologic abnormality. A search of the English language literature failed to discover a description of a similar lesion. From the clinical course and follow-up information, the process appears to be benign. The authors believe the lesion is a form of pseudotumor, and propose that it be designated as "focal hematopoietic hyperplasia of rib" or "hematopoietic pseudotumor."
 ...
PMID:Focal hematopoietic hyperplasia of the rib--a form of pseudotumor. 670 44

Myeloma may be complicated or revealed by spinal cord compression. Out of 105 cases of myeloma admitted to this Department, 6 cases of spinal cord compression were observed, with a favourable outcome after treatment by laminectomy combined with radiotherapy. In 5 cases out of 6, spinal cord compression was either the presenting sign or occurred within the first months after diagnosis. Compression occurred in the thoracic cord in 5 cases, and in the lumbar cord in 1 case. The interval between the first symptom and diagnosis varied greatly (from a few hours to 1 year), as did the degree of paraplegia, which ranged from paraparesis to flaccid paraplegia. A favourable outcome occurs in most other reported cases, in contrast with spinal cord compression from metastases. Treatment (laminectomy-radiotherapy or both) remains controversial.
 ...
PMID:[Spinal cord compression in malignant plasmacytic diseases. Apropos of 6 cases]. 671 66

Twenty-eight persons with contiguous intracranial skull, and often extracranial metastatic disease are reported. These lesions comprised 7.6% of a series of 250 consecutive patients with intracranial metastatic disease. Only three of 28 patients had other intracranial lesions and only seven of 28 patients has other skull lesions demonstrable on computed tomography (CT). Carcinoma of the prostate and breast, multiple myeloma, and neuroblastoma are especially likely to appear in this manner. All metastases enhanced. The bone destruction was so pervasive that in 19 of the patients it was obvious at routine CT settings. In the nine other patients, it could be clearly seen only at bone settings (high window and level). The CT demonstration of an enhancing intracranial mass involving the skull and often the scalp is highly suggestive but not diagnostic of a metastatic lesion.
 ...
PMID:CT of intracranial metastases with skull and scalp involvement. 678 2

Monoclonal antibodies were produced after immunization of mice with a colorectal adenocarcinoma cell line or liver metastasis membranes from a patient with colon adenocarcinoma. Many monoclonal antibodies were found to react with colorectal adenocarcinoma cells but not with normal colon mucosa, blood lymphocytes, myeloma cells or lung epithelial carcinoma cells. Three of these 'colorectal tumour-specific' antibodies appear to define different antigens that were found in the complex monosialoganglioside fraction from 60 to 90% of the colorectal and pancreatic adenocarcinoma tumours or metastases examined but essentially lacking in normal colon mucosa and other normal or tumour tissues tested.
 ...
PMID:Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. 684 Aug 74

Neoplastic plasma cell disorders, multiple myeloma, extramedullary plasmacytoma and solitary plasmacytoma affect the head and neck with different manifestations. Multiple lytic lesions of the jaws and infrequent soft-tissue lesions characterize multiple myeloma's presence. The solitary plasmacytoma of bone is infrequent in the jaws. Wherever it occurs, it is a precursor lesion to multiple myeloma. Extramedullary plasmacytoma has several clinical and biologic forms. The most benign is the local upper airway lesion that is amenable to surgery or radiotherapy and manifests no recurrences. Approximately 40%, however, terminate in osseous and soft-tissue dissemination. The distant involvement has more characteristics of metastases than the diffuse axial skeletal involvement of multiple myeloma; to acknowledge this distribution and the apparently better prognosis, the disseminated form is called myelomatosis.
 ...
PMID:Pathology consultation. Plasma cell tumors of the head and neck. 685 50

In 123 cancer patients with metastatic disease, 129 pathologic fractures of long bones were assessed to determine the rate of osseous union. Bony healing was observed in 67% of malignant fractures from multiple myeloma, in 44% of fractures secondary to metastatic hypernephroma, and in 37% of neoplastic fractures from breast carcinoma. No patient with a pathologic fracture secondary to lung carcinoma demonstrated bony repair, and none of these patients lived for more than six months after fracture. The overall fracture healing rate for the entire study population was 35%. In the group that survived longer than six months, 74% of fractures united. A life expectancy of longer than six months was the primary factor determining osseous healing in all patients. A total radiotherapy dose of 3000 rad or less did not inhibit callus formation. Internal fixation improved the rate of fracture union by 23% as compared with cast immobilization.
 ...
PMID:Fracture healing in metastatic bone disease. 688 64

Three cases of tumors of the mandibular condyle are reported. One patient had metastases from a cutaneous melanoblastoma, another a benign osteochondroma, and the third a plasmocytosarcoma revealing the presence of Kahler disease. The authors emphasize the rare nature of these lesions, in spite of the technical advances made in the radiological and surgical exploration of the temporomandibular joint, and also the large variety of histological types reported in the literature. They discuss the main diagnostic features, especially in isolated lesions in patients with no relevant past history, and stress the importance of surgical biopsy. Therapy varies from surgical treatment in benign tumors, the prognosis being excellent, to usually palliative therapy in malignant lesions.
 ...
PMID:[Tumors of the mandibular condyle (author's transl)]. 693 76

A harmonious cooperation between the oncologist, orthopedist and radiotherapist can result in a more comfortable, more functional, and in some instances, longer life for the patient. Chemotherapy is an effective and important component of the total management of a patient with metastatic cancer. It provides a mode of therapy for all of the manifestations of disseminated cancer, including bone metastases. Combination chemotherapy has been demonstrated to be of important benefit in metastatic bone disease secondary to carcinomas of the breast, prostate and lung (small cell). The results with other types of lung cancer are less impressive. The chemotherapy of metastatic thyroid and renal carcinomas remains disappointing. Of the tumors that metastasize less frequently to bone, testicular and ovarian neoplasms have demonstrated significant responsiveness to combination chemotherapy. Results with Hodgkin's disease, other lymphomas and multiple myeloma are reproducible and may provide palliation and extended survival. Metastatic melanoma, colon cancer and miscellaneous other carcinomas in bone are ordinarily refractory. The limitations of the current modes of assessing response to therapy in osseous lesions impede the ability to recognize and thus, capitalize on effective treatments. New drugs and new combinations of drugs hold promise for the future.
 ...
PMID:Chemotherapy of metastatic cancer in bone. 704 90

In the majority of skeletal metastases, new bone develops simultaneously with bone destruction. The roentgenogram indicates the net effect of these two processes. Where the bone formation predominates, the lesion appears sclerotic. Where bone destruction predominates, it appears lytic. Mixed lesions may also occur. There are two main mechanisms for the new bone formation. Those tumors associated with a suitable fibrous stroma develop islands of intramembranous ossification within the stroma, e.g., metastases from prostatic carcinoma. In the vast majority of metastases bone destruction is associated with reactive new bone formation. The latter is similar to callus associated with fracture repair. Myelomata and lymphomata are not associated with this reactive new bone formation. There are at least two main mechanisms for the bone destruction. The earlier and quantitatively more important phase is mediated via osteoclasts, neoplasms secreting a variety of osteoclast stimulating factors. The main humoral factor in myeloma and the lymphomata is probably osteoclast activating factor (OAF), whereas in the carcinomata it may be prostaglandin. Two thirds of human mammary carcinomata are osteolytically active in vitro. In a co-culture model, the osteolysis can be significantly reduced by prostaglandin inhibitors, diphosphonates and particularly, their combination. At a late stage, neoplastic or monocytic cells are directly responsible for the continuing bone destruction.
 ...
PMID:Mechanisms of lytic and blastic metastatic disease of bone. 710 80


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>